Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Objective: To determine the impact of RAS mutation status on survival and patterns of
recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) …

Background Hepatic resection is considered the optimal potentially curative treatment for
colorectal liver metastases (CRLM). Following resection, up to two-thirds of patients will …

Background In patients with advanced colorectal cancer, KRAS mutation status predicts
response to treatment with monoclonal antibody targeting the epithelial growth factor …

Abstract Purpose: Mutations in PIK3CA [the gene encoding the p110α catalytic subunit of
phosphatidylinositide-3-kinase (PI3K)] play an important role in colorectal carcinogenesis …

BACKGROUND RAS and PIK3CA mutations in metastatic colorectal cancer (mCRC) have
been associated with worse survival. We sought to evaluate the impact of RAS and PIK3CA …

Background: Despite major advances in the management of metastatic colorectal cancer
(mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers …